A Study of OMP-313M32 in Subjects With Locally Advanced or Metastatic Solid Tumors
Status:
Terminated
Trial end date:
2019-05-15
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of OMP-31M32 as a single
agent or in combination with nivolumab. OMP-313M32 is an experimental anti-TIGIT antibody
that was developed to block TIGIT from binding PVR allowing the body's T-cells to destroy
cancer cells.